EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische StudieOpen Access · CC BY 4.0

First-in-human clinical series of a novel conformable large-lattice pulsed field ablation catheter for pulmonary vein isolation

Vivek Y Reddy iD, Elad Anter iD, Petr Peichl iD, Gediminas Rackauskas iD, Jan Petru, Moritoshi Funasako iD, Jacob S Koruth iD, Germanas Marinskis, Mohit Turagam, Audrius Aidietis, Josef Kautzner iD, Andrea Natale iD und 1 weitere

Europace · 30.03.2024 · 26 (4)

DOI: 10.1093/europace/euae090 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Europace, online erschienen am 08.04.2024. Verfasst von Vivek Y Reddy und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Icahn School of Medicine at Mount Sinai, One Gustave Levy Place, Box 1030, New York, NY, USA. Hauptthemen laut MEDLINE: Pulmonary Veins, Atrial Fibrillation, Catheter Ablation, Recurrence. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Affera, Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Pulsed field ablation (PFA) has significant advantages over conventional thermal ablation of atrial fibrillation (AF). This first-in-human, single-arm trial to treat paroxysmal AF (PAF) assessed the efficiency, safety, pulmonary vein isolation (PVI) durability and one-year clinical effectiveness of an 8 Fr, large-lattice, conformable single-shot PFA catheter together with a dedicated electroanatomical mapping system. Methods and results After rendering the PV anatomy, the PFA catheter delivered monopolar, biphasic pulse trains (5–6 s per application; ∼4 applications per PV). Three waveforms were tested: PULSE1, PULSE2, and PULSE3. Follow-up included ECGs, Holters at 6 and 12 months, and symptomatic and scheduled transtelephonic monitoring. The primary and secondary efficacy endpoints were acute PVI and post-blanking atrial arrhythmia recurrence, respectively. Invasive remapping was conducted ∼75 days post-ablation. At three centres, PVI was performed by five operators in 85 patients using PULSE1 (n = 30), PULSE2 (n = 20), and PULSE3 (n = 35). Acute PVI was achieved in 100% of PVs using 3.9 ± 1.4 PFA applications per PV. Overall procedure, transpired ablation, PFA catheter dwell and fluoroscopy times were 56.5 ± 21.6, 10.0 ± 6.0, 19.1 ± 9.3, and 5.7 ± 3.9 min, respectively. No pre-defined primary safety events occurred. Upon remapping, PVI durability was 90% and 99% on a per-vein basis for the total and PULSE3 cohort, respectively. The Kaplan–Meier estimate of one-year freedom from atrial arrhythmias was 81.8% (95% CI 70.2–89.2%) for the total, and 100% (95% CI 80.6–100%) for the PULSE3 cohort.

Conclusion

Pulmonary vein isolation (PVI) utilizing a conformable single-shot PFA catheter to treat PAF was efficient, safe, and effective, with durable lesions demonstrated upon remapping.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary VeinsAtrial FibrillationCatheter AblationRecurrenceCardiac CathetersHumansMaleFemaleMiddle AgedAgedTreatment OutcomeEquipment DesignElectrophysiologic Techniques, CardiacTime FactorsHeart RateAction Potentials

Stichwörter der Autor:innen

Atrial fibrillationCatheter ablationElectroanatomical mapping systemLesion durabilityPulsed field ablationSingle-shot

Autor:innen und Institutionen

  • Department of Cardiology, Icahn School of Medicine at Mount Sinai, One Gustave Levy Place, Box 1030, New York, NY, USA.
  • Department of Cardiology, Homolka Hospital, Prague, Czech Republic.
  • Division of Cardiovascular Medicine, Shamir Medical Center, Be'er Yaakov, Tel Aviv, Israel.
  • Department of Cardiology, Institute for Clinical and Experimental Medicine-IKEM, Prague, Czech Republic.
  • Department of Cardiology, Vilnius University, Vilnius, Lithuania.
  • Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, TX, USA.

ORCID-Profile: Vivek Y Reddy, Elad Anter, Petr Peichl, Gediminas Rackauskas, Moritoshi Funasako, Jacob S Koruth, Josef Kautzner, Andrea Natale, Petr Neuzil

Förderung

  • Affera, Inc

Zitieren

APA

Reddy, V. Y., Anter, E., Peichl, P., Rackauskas, G., Petru, J., Funasako, M., Koruth, J. S., Marinskis, G., Turagam, M., Aidietis, A., Kautzner, J., Natale, A., & Neuzil, P. (2024). First-in-human clinical series of a novel conformable large-lattice pulsed field ablation catheter for pulmonary vein isolation. Europace, 26(4). https://doi.org/10.1093/europace/euae090

Vancouver

Reddy VY, Anter E, Peichl P, Rackauskas G, Petru J, Funasako M, et al. First-in-human clinical series of a novel conformable large-lattice pulsed field ablation catheter for pulmonary vein isolation. Europace. 2024;26(4). doi:10.1093/europace/euae090

BibTeX
@article{Reddy2024,
  author = {Reddy, Vivek Y and Anter, Elad and Peichl, Petr and Rackauskas, Gediminas and Petru, Jan and Funasako, Moritoshi and Koruth, Jacob S and Marinskis, Germanas and Turagam, Mohit and Aidietis, Audrius and Kautzner, Josef and Natale, Andrea and Neuzil, Petr},
  title = {First-in-human clinical series of a novel conformable large-lattice pulsed field ablation catheter for pulmonary vein isolation},
  journal = {Europace},
  year = {2024},
  volume = {26},
  number = {4},
  doi = {10.1093/europace/euae090}
}
Kostenlos starten →